Addex Therapeutics Reports 2025 Third Quarter Financial Results and Provides Corporate Update
Addex Therapeutics Ltd - American Depositary Shares (ADXN)
Company Research
Source: GlobeNewswire
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, December 4, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today reported its financial results for the three-month and nine-month periods ended September 30, 2025, and provided a corporate update. “We continue to make great progress with our GABAB positive allosteric modulator (PAM) candidate in chronic cough following demonstration of robust anti-tussive activity in multiple chronic cough preclinical models earlier in the year as well as advancing dipraglurant for post-stroke recovery,” said Tim Dyer, CEO of Addex. Operating Highlights: Continued advancing GABAB PAM chronic cough candidate through preclinical developmentAdvancing the preparation of dipraglurant for clinical studies in post-stroke recovery Key Q3 2025 Financial Data CHF’ thousands Q3 25 Q3 24
Show less
Read more
Impact Snapshot
Event Time:
ADXN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ADXN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ADXN alerts
High impacting Addex Therapeutics Ltd - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
ADXN
News
- Addex Therapeutics Ltd (ADXN) Q3 2025 Earnings Call Highlights: Strategic Advances Amidst ... [Yahoo! Finance]Yahoo! Finance
- Addex Therapeutics to Report 2025 Third Quarter Financial Results And Host Conference Call on December 4, 2025 [Yahoo! Finance]Yahoo! Finance
- Addex Therapeutics to Report 2025 Third Quarter Financial Results And Host Conference Call on December 4, 2025GlobeNewswire
- Addex Increases Issued Share Capital to Create Treasury SharesGlobeNewswire
- Addex Therapeutics (NASDAQ:ADXN) had its "sell (d+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
ADXN
Sec Filings
- 12/4/25 - Form 6-K
- 11/19/25 - Form F-3
- 10/29/25 - Form 6-K
- ADXN's page on the SEC website